Demographic data and clinical characteristics of patients
| Parameter | NMO | POAG | Healthy controls | P value | ||
| Patients (n) | 124 | NMO-ON: 62 | 102 | G-E: 59 | 62 | – |
| NMO+ON: 62 | G-A: 43 | |||||
| Eyes (n) | 208 | NMO-ON: 95 | 124 | G-E: 74 | 90 | – |
| NMO+ON: 113 | G-A: 50 | |||||
| Age, median, (IQR), years* | 37 (29.5–48) | 43 (35–53.5) | 40.5 (29–55) | <0.0001 | ||
| Sex, female:male† | 110:14 | 33:69 | 36:27 | <0.0001 | ||
| Percentage of patients with AQP4-IgG+ | 94.4% | – | – | – | ||
| BCVA, mean (SD) | 0.57 (0.37) | 0.86 (0.22) | 1.02 (0.13) | <0.0001 | ||
*Kruskal-Wallis test, p<0.05 was considered to be statistically significant.
†χ2 test, p<0.05 was considered to be statistically significant.
BCVA, best-corrected visual acuity.